Nirmatrelvir/ritonavir (Paxlovid) is an oral treatment for COVID-19 recently authorized for patients aged 12 years or older who weigh at least 88 pounds (40 kg). It is indicated for patients with mild to moderate COVID-19 who are at high risk of developing severe disease. This includes people with CF. There are expected interactions with cystic fibrosis transmembrane conductance regulator modulators (Trikafta, Kalydeco, Orkambi, Symdeco) and this medication whcih can lead to increased levels of the modulator in people. We strongly encourage you to call the CF Center about dose adjustments for your modulator and all other medications in the chronic treatment regimen if you need to use Paxlovid.